Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

Reports Q2 revenue $26.2M, consensus $26.03M. Reports Q2 Non-GAAP net loss from operations $4.2M vs. a net loss from operations $6.3M last year. Cash, cash equivalents and marketable securities totaled $338.8M as of June 30. “Strong execution across our business defined the second quarter, driven by commercial growth, disciplined operations, and continued progress on ampreloxetine. YUPELRI posted another strong quarter in the U.S., and its recent approval in China triggered a $7.5M milestone payment. With the completion of the strategic monetization of our TRELEGY royalty interest, which brought in $225M, these accomplishments have meaningfully strengthened our business,” said Rick E Winningham, CEO of Theravance Biopharma (TBPH). “We enter the second half of 2025 with momentum and a clear focus on ampreloxetine. We remain on track for completing the enrollment in our pivotal Phase 3 CYPRESS study in late summer, and continue to prepare for reporting top-line data approximately six months later.”